《大行报告》花旗上调友邦(01299.HK)目标价至116元 维持「买入」评级
花旗发表研究报告指,虽然受疫情反弹影响,友邦保险(01299.HK)去年第四季新业务价值(NBV)表现较差,将全年NBV跌幅预测由18%进一步下调至31%,但考虑到中国内地业务扩张,将2022年NBV增长率从19%上调至26%。
该行又将第二阶段及终端年化新保费(ANP)增长分别上调至10%及3.75%,预料在潜在的积极资本控制措施下,将刺激跨境保险产品销售。
花旗表示,持续看好友邦保险,特别关注其在内地的长期结构性增长机会,估计通关後来港内地人士业务可能强劲反弹,此外内地放宽资本管制,以及大湾区金融市场互联互通将为友邦带来新分销渠道。花旗将目标价由84元上调至116元,予「买入」评级,并微调2020至2022年每股盈测。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.